Rossmore Private Capital’s Matinas BioPharma MTNB Stock Holding History

Rossmore Private Capital’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-350	Closed	-$2.77K	–	235
2024 Q2	$2.77K	Hold	350	–	–	﹤0.01%	231
2024 Q1	$4.74K	Hold	350	–	–	﹤0.01%	233
2023 Q4	$3.78K	Hold	350	–	–	﹤0.01%	232
2023 Q3	$2.27K	Hold	350	–	–	﹤0.01%	229
2023 Q2	$6.3K	Hold	350	–	–	﹤0.01%	231
2023 Q1	$8.22K	Hold	350	–	–	﹤0.01%	229
2022 Q4	$8.75K	Hold	350	–	–	﹤0.01%	227
2022 Q3	$11K	Hold	350	–	–	﹤0.01%	221
2022 Q2	$14K	Buy	+350	New	+$13.3K	﹤0.01%	227

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return

Rossmore Private Capital's MTNB Position: Q3 2024 in Review

Rossmore Private Capital sold out of Matinas BioPharma (MTNB) in Q3 2024, closing a stake of 350 shares — an estimated $2.77K sold.

Rossmore Private Capital first reported a position in MTNB in Q2 2022 and held it in 9 quarters. The position peaked at $14K in Q2 2022. 18 funds tracked by Wall St. Rank hold MTNB as of Q3 2024.

Rossmore Private Capital reported no remaining Matinas BioPharma position as of Q3 2024 after selling out during the quarter.
Rossmore Private Capital sold 350 Matinas BioPharma shares in Q3 2024, an estimated $2.77K.
Rossmore Private Capital first reported a position in Matinas BioPharma in Q2 2022 and held it in 9 quarters.
Rossmore Private Capital's Matinas BioPharma position peaked at $14K in Q2 2022.
18 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2024.

Based on Rossmore Private Capital's 13F filing for Q3 2024, filed 5 Nov 2024.